Osteoporosis Canada warns GLP-1 users about bone-health risks: what Canadian patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

---

In a June 4, 2026 webinar hosted by Osteoporosis Canada, endocrinologist Dr. Claudia Gagnon (Université Laval, CHU de Québec) told Canadian clinicians and patients that GLP-1 receptor agonist medications, including semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for weight management) and tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity), produce meaningful weight loss but also carry real risks for bone density and lean muscle mass that must be actively managed. For the roughly 4 million Canadians living with obesity and the growing number prescribed these drugs off-label or through provincial obesity programs, the message is direct: losing weight quickly on a GLP-1 is not automatically safe for your skeleton.

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a gut hormone that slows gastric emptying, reduces appetite, and signals satiety to the brain. When people eat substantially less, they often take in less calcium, protein, and vitamin D. Rapid weight loss from any cause, including drug-induced weight loss, is associated with reductions in bone mineral density. The concern Dr. Gagnon raised is that GLP-1 drugs change not just how much people eat but also their food preferences and daily habits, which can compound nutritional gaps. Muscle loss (sarcopenia) is a parallel risk: when caloric intake drops sharply without structured resistance training, the body draws on lean tissue as well as fat.

What this means in Canada

Health Canada has approved semaglutide (Wegovy) for chronic weight management in adults with a body mass index of 30 or above, or 27 or above with at least one weight-related condition. Tirzepatide (Zepbound) received Health Canada approval for obesity in late 2024. Both drugs are FDA-approved in the United States as well. Health Canada has not issued a specific safety communication on bone loss linked to GLP-1 drugs as of June 2026, though the product monographs for these medications note that weight loss itself can affect bone.

Provincial coverage is inconsistent. In Ontario, OHIP does not cover Wegovy; the Ontario Drug Benefit program covers Ozempic for type 2 diabetes but not for obesity alone. In Quebec, RAMQ covers semaglutide for diabetes indications; coverage for the obesity indication remains limited. British Columbia's PharmaCare and Alberta's AHCIP similarly cover the diabetes indication more readily than the obesity indication. Patients paying out of pocket for Wegovy in Canada typically spend $300 to $500 CAD per month. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement specifically on GLP-1 drugs and bone health as of this writing. Osteoporosis Canada's June 2026 webinar is the most current Canadian clinical guidance available on this intersection.

For Canadians seeking GLP-1 prescriptions through digital health platforms, services such as Felix, Maple, and Science & Humans (scienceandhumans.com) can connect patients with licensed Canadian prescribers. Platforms such as Hone Health and Midi are US-only and do not serve Canadian patients.

Why this matters

Osteoporosis affects an estimated 2 million Canadians, and fracture risk rises sharply after age 50, particularly in women after menopause. Bone loss from rapid weight reduction adds to the bone loss that already accompanies declining estrogen. A patient who starts a GLP-1 drug during perimenopause or postmenopause is therefore managing two simultaneous threats to bone density.

Dr. Gagnon's research background is directly relevant here. Her work at the CIHR (Canadian Institutes of Health Research)-funded CHU de Québec Research Centre has focused on how obesity, diabetes, and their treatments, including bariatric surgery, affect bone metabolism. The parallel to bariatric surgery is instructive: post-surgical patients have long been monitored for bone loss, and the same logic now applies to pharmacological weight loss. A 2023 analysis published in the Journal of Bone and Mineral Research found that semaglutide-treated participants in the STEP trials lost bone mineral density at the hip, even after adjusting for the amount of weight lost, suggesting a possible direct effect beyond caloric restriction alone.

Muscle loss compounds the fracture risk. Sarcopenia reduces the protective effect of muscle on bone during a fall and increases fall risk itself. When GLP-1 users lose weight without preserving lean mass, their fracture risk profile can worsen even as their metabolic profile improves.

What Canadian patients should know

Dr. Gagnon outlined several strategies during the Osteoporosis Canada webinar. Patients on GLP-1 drugs should prioritize adequate protein intake, aiming for at least 1.2 grams per kilogram of body weight per day, which can be difficult when appetite is suppressed. Calcium intake of 1,000 to 1,200 mg per day (from food first, supplements if needed) and vitamin D supplementation of at least 800 to 2,000 IU daily are consistent with Osteoporosis Canada's standing recommendations for adults at risk.

Resistance exercise is the most direct tool for preserving lean muscle during weight loss. Walking alone is not sufficient. Patients should aim for two to three sessions per week of weight-bearing or resistance activity, adapted to their current fitness and any existing fracture risk.

Baseline bone mineral density testing (a DXA scan) is worth discussing with a family physician or endocrinologist before or shortly after starting a GLP-1 drug, particularly for patients over 50, postmenopausal women, or anyone with prior fractures. In most provinces, DXA scans are covered when ordered for patients who meet clinical criteria for osteoporosis risk assessment.

Patients already on osteoporosis medications such as alendronate (Fosamax), zoledronic acid (Aclasta), or denosumab (Prolia) should tell their prescribing physician they are starting a GLP-1 drug, so monitoring schedules can be adjusted.

Limitations and open questions

The evidence base here is still developing. Most GLP-1 bone-health data comes from trials designed to measure cardiovascular or glycemic outcomes, not skeletal endpoints. Trial durations have generally been two years or less, which may not capture long-term bone effects. It is not yet clear whether tirzepatide carries the same bone risk profile as semaglutide, or whether the risk differs between patients with and without type 2 diabetes.

Health Canada has not issued updated labelling or a specific advisory on bone loss for GLP-1 drugs as of June 2026. The SOGC has not issued a position statement on GLP-1 use in perimenopausal or postmenopausal women. Osteoporosis Canada's webinar represents expert clinical opinion, not a formal guideline. Patients and clinicians should watch for updated guidance from both bodies as longer-term trial data accumulates.

The question of whether GLP-1 drugs have a direct biological effect on bone cells, separate from weight loss and reduced food intake, remains open. Some receptor expression data suggests GLP-1 receptors are present in osteoblasts, but the clinical significance of this is unresolved.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.